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Summary 
Tumor necrosis factor (TNF) produced by tumor cells after gene transfer can effectively suppress 
the growth of locally growing tumors. We wanted to test the effects of "local" TNF on the 
growth of a highly metastatic cell line. Therefore, arecombinant retrovirus allowing expression 
of the TNF gene by the B-actin promotor has been constructed and used to infect the two tumor 
cell lines EB and ESB, which grow as solid tumor or metastasize, respectively. Expression of 
TNF by EB cells resulted in their rapid and dose-dependent rejection. In sharp contrast, mice 
injected with ESB cells producing similar amounts of TNF showed no signs of tumor suppression, 
but rather had reduced survival rates that correlated with enhanced hepatic metastases. The accelerated 
formation of liver metastases by ESB TNF cells could be reversed by an anti-TNF mAb. These 
results demonstrate he opposite ffects TNF may have on tumor growth: suppression of a locally 
growing tumor and promotion of metastasis formation. 
T NF has been identified by its direct cytotoxic effects on some tumor cells. In the meantime, however, it has be- 
come clear that TNF is a multifunctional, immunoregula- 
tory cytokine with a broad spectrum of activities on hema- 
topoetic and nonhematopoetic cell types (for review, see 
references 1 and 2). Its tumoricidal activity in vivo seems to 
be mediated largely by immunological mechanisms (3, 4). 
Several TNF gene-modified apparently nonmetastasizing 
tumor lines have been shown to be suppressed in vivo in- 
volving both T ceil-independent and --dependent mechanisms 
(5-10). It is currently not known which molecular mecha- 
nisms are involved in the TNF-induced antitumor response. 
However, it is reasonable toassume that the rapid and strong 
inflammatory reaction in TNF-producing tumors (6, 10) is 
influenced by the action of TNF on endothelial cells, e.g., 
the induction of chemotactic factors for neutrophils or mac- 
rophages (11, 12), which could facilitate invasion of tumor- 
reactive cells. Moreover, TNF has been shown to induce several 
adhesion molecules on endothelial cells (13) and modulates 
endothelial cell coagulant properties, thereby increasing vas- 
cular permeability (14). Similar mechanisms that cause inflam- 
mation in TNF-producing tumors could also contribute to 
metastasis, which involves invading the host tissue, penetrating 
the blood vessels' endothelium, and establishing rowth at 
a secondary site. Due to these potentially opposite ffects of 
TNF on tumor growth, we have addressed the question of 
which activity of TNF would dominate, its tumor suppres- 
sive effect or its possible involvement in tumor cell move- 
ment when expressed by a cell line that has the potential to 
metastasize. 
Materials and Methods 
Cell Lines. EB is a methylcholanthrene-induced DBA/2 T lym- 
phoma formerly called L5178Y, and ESB (previously L5178Y-M) 
is a spontaneous metastasizing variant of EB (15, 16). Both cell 
lines were cultured in KPMI 1640, 10% FCS, and antibiotics. The 
culture medium of ESB cells contained additionally 50 #m 2-ME. 
Helper virus-containing cell lines psi2 (17) and PA317 (18) were 
cultured in DME, 10% FCS. 
Generation of Recombinant Retrovirus and Viral Infection. The 
mouse TNF cDNA was isolated by reverse PCK using primers 
specific for regions that contain translation start or stop signals, 
respectively, and additionally BamHI sites to facilitate doning (5' 
CTGGATCCAGAAAAGACACCATGAGCACA 3' and 5' ATG- 
GATCCACACCCATTCCCTTCACAGA 3'). Substrate for PCK 
was cDNA derived from LPS-stimulated mouse spleen ceUs. Acti- 
vation of spleen cells by LPS, KNA preparation, cDNA synthesis, 
and PCK was done as described (19). The 0.74-kb TNF cDNA 
BamHI fragment was used to replace the neomycin gene of vector 
pBA-neo (20). This plasmid (pBA-TNF; 6) was digested with XhoI 
and partially with BamHI, a ~,l-kb fragment containing the/~-actin 
promotor, and the mouse TNF cDNA was provided with XhoI 
linker (1030; New England Biolabs, Schwalbach, FKG) and cloned 
into vector N2 (21). The resulting vector pNBT was supposed to 
express TNF by the B-actin promoter and the neomycin gene by 
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the retroviral LTR. Retroviruses were generated as described (6). 
Briefly, the amphotropic packaging line PA317 was transfected using 
an eucaryotic transfection kit (200285; Stratagene, La Jolla, CA) 
with plasmid pNBT, and cells resistant to G418 (1 mR/m1) were 
selected (PA317-NBT). Then, the ecotropic packaging line psi2 was 
infected by overnight exposure to the culture supematant of PA317- 
NBT cells in the presence of 5 #g/m1 polybrene, and G418-resistant 
cells were selected (psi-NBT). Cell-free conditioned medium 
(subconfluent monolayers cultured for 24 h) contained 5 x 104/ml 
(PA317-NBT cells) or 3 x l(Y/ml (psi-NBT cells) G418 R CFU, 
which was determined by infection of NIH3T3 cells with serial 
dilutions of supernatant of either cell culture. Similarly, EB and 
ESB cells were infected (106 cells in 4 ml culture medium sup- 
plemented with 4 ml virus-containing culture supernatant ofpsi- 
NBT cells and 5 #g/ml polybrene for 16 h) and cloned after G418 
selection. All infected EB or ESB cells used in this study were nega- 
tive for replication-competent helper virus as judged by the ina- 
bility of culture supernatants of the cells grown for at least 2 wk 
to generate G418 R colonies upon ,~xposure to NIH3T3 cells. 
TNF Bioassay. TNF activity was measured by the L929 cyto- 
toxicity assay as described (6) with recombinant mouse TNF (B1243; 
Genzyme, Cambridge, MA) as standard. A neutralizing anti-TNF 
mAb (Vlq; 22) was used at a concentration f 1 #g/ml for specificity 
control Detection limit of the L929 assay was 4 pg/ml. 
Analysis of Tumorigenicity. An indicated number of cells was 
injected subcutaneously into the belly region of 6-8-wk-old female 
DBA/2 mice (Bomholtgard, Ky, Denmark) in a volume of 0.2 ml 
in Dulbecco's PBS. Tumor size was measured as described (6). He- 
patic metastases were macroscopically evaluated at different ime 
points after tumor cell injection. In some experiments, primary 
tumors or metastases were excised and recultured inorder to deter- 
mine TNF expression after in vivo growth. To analyze ESB 
metastasis n the presence of anti-TNF mAb, 200 #g Vlq mAb 
or isotype-matched control mAb were injected together with tumor 
cells subcutaneously, and the same dose of mAbs was injected in- 
traperitoneally on days 0, 2, 4, 6, and 8. 
Results 
TNF Expression by Tumor Cell Lines EB and ESB after In- 
fection with a TNF-specific Retrovirus. For expression of TNF 
in tumor cell lines EB and ESB, a Moloney murine leukemia 
virus-based retroviral vector named pNBT was constructed 
that contains the neomycin gene as selectable marker and the 
mouse TNF gene under the control of viral LTK and/3-actin 
promotor, respectively (Fig. 1). Virus-producing cells (psi- 
NBT) were established and used to infect EB and ESB cells. 
After infection, G418 p" ceUs were cloned and TNF activity 
in the culture supematant was determined. Neither EB nor 
ESB cells produced detectable amounts of TNF (Table 1). 
The bulk culture of infected EB cells (EB-TNF) or clones 
derived thereof (EB-T9 and EB-Tll)  produced between 15 
and 80 pg/ml TNF. The bulk culture of infected ESB cells 
(ESB-TNF) and derived clones (ESB-T2 and ESB-T7) pro- 
duced up to 200 pg/ml TNF. The cytotoxic activity on L929 
cells of aU retroviraUy infected cells could be neutralized by 
an anti-TNF mAb (not shown). It should be noted that both 
EB and ESB cells were resistant o TNF, and TNF expres- 
sion did not alter the growth rates of the cells in vitro. As 
control, ESB cells were also infected with control virus N2, 
NBT : 
LTR NEO BA mTNF LTR 
X B BX 
i 1 Kb  j 
Figure 1. Structure of recombinant retrovirus used for TNF expres- 
sion. LTR, long terminal repeat; neo, neomycin gene; BA, B-actin pro- 
motor; mTNF, mouse TNF cDNA; X, XhoI; B, BamHI. 
Table 1. TNF Expression after Gene Transfer into 
Cell Lines EB and ESB 
Cell line TNF activity 
pg/ml per I06 cells/24 h 
EB 
EB-TNF (bulk) 15 
EB-T9 80 
EB-T11 15 
ESB 
ESB-TNF (bulk) 20 
ESB-T2 200 
ESB-T7 130 
ESB-N (clones 1-5) 
Table 2. Tumor Suppression Resulting from TNF Expression 
by EB Cells 
Exp. Cell line Injected cells 
No. of mice 
with tumor/ 
no. of mice 
injected 
x I0 ~ 
EB 2.5 5/5 
EB-TNF (bulk) 2.5 2/4 
EB 2.5 10/10 
1.0 9/10 
0.5 5/5 
0.1 4/5 
EB-T9 2.5 3/8 
1.0 0/5 
0.5 0/5 
0.1 0/5 
EB-T11 1.0 3/5 
(2) 
(3) 
(2) 
Cells at the indicated number were injected subcutaneously into DBA/2 
mice and tumor growth was observed for 4 mo. The numbers of mice 
that transiently developed a tumor are given in parentheses. 
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Figure 2. Mortality curves of mice injected subcutaneously with the 
indicated cells. (a) Parental ESB cells have been compared with TNF- 
transduced clones ESB-T2 and ESB-T7 and bulk culture ESB-TNF. (b) TNF- 
transduced ESB-T7 cells have been compared with five clones of mock- 
infected ESB cells. Each group consisted of five or six mice. 
and five O418 R clones were established (ESB-N1 to -N5) 
that did not produce TNE 
Tumor Growth of TNF-producing EB Cells Is Suppressed. EB 
Table 3. Survival Rates of DBA/2 Mice Injected with 
Decreasing Numbers of Cells 
50% survival 
Cell line Cell number in days (•  SD) 
ESB 10 s 28.2 • 9.1 (5/5) 
10 4 31.8 • 11.5 (5/5) 
103 37.3 • 14.8 (4/5) 
ESB-T7 10 s 13.2 _+ 3.8 (5/5) 
104 21.0 • 6.5 (5/5) 
103 19.6 • 5.4 (5/5) 
The numbers of mice having died per number of mice in experiments 
are given in parentheses. 
cells and their TNF-producing derivatives were injected into 
syngendc DBA/2 mice and tumor growth was analyzed (Table 
2). Injection of 2.5 x 106 EB and EB-TNF (bulk) cells 
showed that EB cells grew as a tumor in all cases, whereas 
EB-TNF cells were either rejected or developed to a tumor 
with delay. In a second experiment umor growth in mice 
injected with clones EB-T9 and EB-Tll was compared with 
that of EB cells. The low TNF-producing EB-Tll cells grew 
as a tumor with significant delay or were rejected. EB-T9 
ceils (producing higher amounts of TNF) were completely 
rejected when up to 106 cells were injected. At 2.5 x 106 
cells rejection occurred in five of eight mice. In contrast, nearly 
all mice injected with parental EB cells developed a tumor 
when as few as 10 s cells were injected. These results confirm 
Figure 3. Liver metastases in mice injected subcutaneously with2.5 x 106 ESB (a) or TNF-producing ESB-T2 cells (b) 8 d before. This result was 
confirmed in at least five other mice per group injected with ESB compared with ESB-T2 or ESB-T7 cells. 
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Tab le  4. Treatment with an Anti-TNF mAb of Mice Injected with Indicated Cells Results in Reduction of Liver Metastases 
Metastases in liver No. of 
Cell line mAb injected Mean survival of moribunds livers analyzed 
d 
ESB-T2 - 9.6 _+ 0.5 + + + 3 
ESB-T2 Ant i -TNF  8.2 _+ 0.4 + 5 
ESB-T2 Control  8.6 + 0.9 + + + 4 
ESB-T7 - 8.2 + 0.4 + + + 3 
ESB-T7 Anti-TNF 8.4 + 0.5 + 4 
ESB-T7 Control 7.8 _+ 0.4 + + + 2 
Mice were injected subcutaneously with 2.5 x 10~ cells and mAbs as indicated. The experiment was done with five mice per group. Those mice 
that were accessible when moribund were analyzed for liver metastases. +,  liver was clearly enlarged with <100 macroscopically visible metastases; 
+ + +,  metastases spread over the whole liver (>1,000). 
observations with several other TNF gene-transfected locally 
growing tumors that rejection occurred in a TNF dose- and 
cell dose-dependent manner. 
TNF Production by ESB Cells Accelerates Metastasis and An- 
imal Death. ESB cells and their derivatives were injected into 
DBA/2 mice. At 2.5 x 106 cells, all ESB-injected mice died, 
with a mean survival of 14.6 + 2.9 d (Fig. 2 a). All mice 
injected with TNF-producing cells ESB-TNF, -T2, or -T7 
also died, however, within 8-10 d on average. Similar results 
were obtained in three other experiments. The difference in 
survival rates of mice was even more obvious when lower 
numbers of ESB-T7 in comparison with ESB cells were in- 
jected (Table 3). To exclude the possibility that the reduced 
survival of mice injected with TNF-producing cells resulted 
from cloning artifacts, mice were injected with mock-infected 
clones ESB-N1 to -N5 in comparison with ESB-T7 cells (Fig. 
2 b). Mice from all groups injected with non-TNF-producing 
cells survived significantly longer (p < 0.005) than those in- 
jected with TNF-producing ESB-T7 cells. 
Since metastasis ofESB cells into a number of organs, most 
obviously into the liver, is well established (16), livers of mice 
injected 8 d before with either ESB-T2 or ESB cells were 
macroscopically analyzed. Whereas livers of ESB cell-injected 
animals contained <100 metastases, ESB-T2 cell injection led 
to livers spread with >1,000 metastases. An example that was 
similar in all analyzed cases (each with five livers of ESB-, 
ESB-T2-, and ESB-T7-injected mice) is shown in Fig. 3. R.ecul- 
tivation of tumors and liver metastases from mice injected 
with ESB-T2, ESB-T7, and ESB cells and detection of TNF 
activity in the culture supernatant confirmed that ESB-T2 
and ESB-T7 tumors, but not ESB tumors or metastatic cells, 
still produced TNF (not shown). 
To directly attribute the increasing number of liver 
metastases toTNF, ESB-T2 and -T7 cells were injected into 
DBA/2 mice in parallel with a neutralizing anti-TNF mAb, 
a control mAb, or without mAb. Mice that were moribund 
were analyzed for liver metastases (Table 4). While mice in- 
jected with ESB-T2 or -T7 cells alone or control mAb had 
widespread liver metastases, the liver of those mice injected 
with the anti-TNF mAb were enlarged but barely showed 
metastases. However, the reduction in liver metastases bythe 
anti-TNF mAb did not correlate with a longer survival time 
in any of the groups. 
Discussion 
By TNF gene transfer into ovary (5), skin (7), plasmacy- 
toma (6), or sarcoma tumor cell lines (8), it has been shown 
that TNF locally expressed at the tumor site effectively sup- 
presses tumor growth. This observation is extended here to 
EB cells previously classified as T cell lymphoma (16). The 
results with EB cells also confirm that low nontoxic amounts 
of TNF produced by the tumor cells are sufficient o exert 
effective antitumor activity. In previous tudies the antitumor 
effect of transfected TNF has consistently been shown to be 
immunologically mediated and CD8 + T cells were required 
for complete tumor eradication (8, 10). A similar mechanism 
seems likely for EB cells, which are immunogenic and elicit 
an effective cytolytic CD8 + T cell response in the absence 
of CD4 + T cells (23). 
The ESB tumor arose in a mouse after injection of EB cells 
(15) and, therefore, both cell lines seem to be clonaUy related. 
ESB cells are characterized by a particularly fast metastatic 
spread into various organs, most pronounced in the liver (16). 
In contrast to EB, TNF expression by ESB cells did not cause 
tumor suppression but rather enhanced metastatic spread and 
reduced the survival time of mice injected with these, cells. 
The acceleration ofhepatic metastasis of TNF-producing ESB 
cells was revertible by an anti-TNF mAb, which also slightly 
reduced liver metastasis n mice injected with parental ESB 
cells (data not shown), suggesting some contribution of host's 
TNF for tumor cell spread. The reason why anti-TNF mAb 
application did not prolong survival of mice injected with 
TNF-producing cells is not clear, but could be explained by 
a failure of the mAb to efficiently prevent metastasis into other 
organs. However, it argues against he possibility that reduced 
survival resulted from liver toxicity by TNF. 
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The mechanism by which TNF increased hepatic metastases 
may involve any of its multiple effects on endothelial cells. 
TNF upregulates vascular cell adhesion molecule, intercel- 
lular adhesion molecule, and endothelial leukocyte adhesion 
molecule 1on endothelial cells (13) and directly causes trans- 
endothelial cell migration of PMN (14). Notably, ESB cells 
are LFA-1 + , VLA-4 + , and Me114 +, whereas EB cells are 
LFA-1 +, VLA-4-, and Me114- (data not shown). Thus, 
ESB cells express ligands for adhesion molecules on endothelial 
cells, which could facilitate arly arrest in the circulatory system 
and enable ESB-derived TNF to allow stabilization of this 
interaction by upregulation of adhesion molecules on en- 
dothdial cells. Furthermore, local TNF may stimulate trans- 
endothelial migration of ESB cells, similar as has been ob- 
served for neutrophils in in vitro systems (for review, see 
reference 14). In this regard it is of interest that TNF-activated 
vascular endothelium increases adhesion of human melanoma 
cells (24) and that some melanoma lines express TNF (25). 
The precise mechanism, however, by which TNF promotes 
metastasis of ESB ceils has to be determined. 
The failure of TNF to suppress ESB metastasis could re- 
late to the rapid dissemination of ESB cells and/or to the in- 
ability of ESB-derived TNF to induce an efficient inflamma- 
tory response to the tumor, unlike what had been observed 
in other models (6, 8, 10). Evidence for the latter possibility 
was obtained from immunohistologic analysis. Like ESB cells, 
ESB-T7 tumors were not infiltrated by T ceils (CD4 + and 
CD8 +) within the first 8 d, nor was the CR3 + cell infiltrate 
increased in comparison to ESB tumors (data not shown). 
Furthermore, we did not observe any growth retardation of 
TNF-producing ESB ceils at the injection site until death 
of the animals. 
TNF has previously been implicated in metastasis. Giavazzi 
et al. (26) have described augmented experimental metastases 
in nude mice injected intravenously with TNF. Malik et al. 
(27) have observed that intraperitoneally injected TNF- 
producing CHO cells killed the mice earlier than control CHO 
cells and showed a more pronounced tumor infiltration of 
the peritoneal wall. The peritoneum in this system seems to 
be a privileged site since the same cells injected subcutane- 
ously were suppressed in growth (5). The site of TNF produc- 
tion has been shown to determine its metabolic effects (28). 
Our results differ from previous ones by: (a) analyzing 
metastasis in subcutaneously rather than intravenously injected 
animals; (b) providing TNF locally and at an injection site 
that (with the exception of ESB cells) consistently revealed 
an effective antitumor esponse; and (c) analyzing metastasis 
in immunocompetent mice. Therefore, our results allow di- 
rect comparison of the tumor-suppressive with the tumor- 
promoting effects of TNF. However, we cannot exclude that 
with other metastatic tumor cells that spread slower and via 
different mechanisms the tumor-suppressive activity of TNF 
dominates over its involvement in metastases. 
Finally, our results may have implications for immunother- 
apeutic approaches in cancer treatment. The use of TNF 
gene-transfected tumor cells as vaccines (29) raises the ques- 
tion as to whether such cells are reliably able to elicit an an- 
titumor response and, if tumor cells have already metasta- 
sized, whether TNF expression might favor the metastatic 
process. On the other hand, the genetic engineering of tumor- 
infiltrating T lymphocytes toproduce TNF could indeed alter 
their in vivo characteristics (30), in particular with respect 
to their motility. At least for ESB cells, <100 pg/ml secreted 
TNF was sufficient o promote cell movement. Whether 
TNF-producing tumor-specific T cells localize more efficiently 
to the tumor is under investigation. 
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